PARP inhibitor Olaparib overcomes Sorafenib resistance through reshaping the pluripotent transcriptome in hepatocellular carcinoma.

Autor: Yang, Xiao-Dong1,2,3 (AUTHOR), Kong, Fan-En1,2 (AUTHOR), Qi, Ling1,2 (AUTHOR), Lin, Jia-Xin1,2 (AUTHOR), Yan, Qian3,4 (AUTHOR), Loong, Jane Ho Chun5 (AUTHOR), Xi, Shao-Yan6 (AUTHOR), Zhao, Yue7 (AUTHOR), Zhang, Yan8 (AUTHOR), Yuan, Yun-Fei6 (AUTHOR), Ma, Ning-Fang1,2,9 (AUTHOR), Ma, Stephanie5 (AUTHOR), Guan, Xin-Yuan3,6 (AUTHOR) xyguan@hkucc.hku.hk, Liu, Ming1,2,9 (AUTHOR) liuming@gzhmu.edu.cn
Zdroj: Molecular Cancer. 1/23/2021, Vol. 20 Issue 1, p1-7. 7p.
Databáze: Academic Search Ultimate
Nepřihlášeným uživatelům se plný text nezobrazuje